potential

For those new to EMS, the script below was announced last year which brought a lot of attention to EMS. The trial progress was delayed considerably since then resulting in SP depreciation, however recently the company announced that recruitment for their phase III trial is almost completed and this puts EMS in a position where they can now start to realise theirtrue potential.


ArTiMist™ listed as one of the 5 most
promising drugs in Phase III trials.
Eastland is pleased to announce that one of the world’s leading Pharmaceutical Intelligence
groups, Thomson Reuters, has listed Eastland’s lead project ArTiMist™ as being one of the 5
most promising drugs to enter into Phase III trials. The whole article can be viewed on the
Thomson Reuters website:
thomsonreuters.com/content/science/pdf/ls/pharma_matters/the_ones_to_watch.pdf
Eastland’s CEO Stephen Carter stated that “the ArTiMist™ project is World Class and we are
pleased to see that a group as prominent as Thomson Reuters acknowledges the potential
importance of the ArTiMist™ project in the global fight against malaria.”
Note: The article refers to Star Medical, a wholly owned subsidiary of Eastland Medical
Systems Ltd. Star Medical has now been deregistered. All of Star Medicals assets and
undertakings were absorbed into Eastland Medical Systems Ltd.